



CS/BSE/NSE/PR/2016-2017  
November 14, 2016

**To**  
**The Manager**  
**Listing Department**  
**National Stock Exchange of India Limited**  
**Exchange Plaza, Bandra Kurla Complex**  
**Bandra (E), Mumbai – 400 051**

**To**  
**The General Manager**  
**Department of Corporate Services**  
**BSE Limited**  
**25th Floor, P. J. Towers,**  
**Dalal Street, Mumbai - 400 001**

**Stock Code: SUVEN - EQ**

**Stock Code: 530239**


Dear Sir/Madam,

**Sub: Press Release**

.....  
With reference to above subject, please find enclosed Press Release of our company titled **“Suvan Life Sciences presenting at Society for Neuroscience (SFN-2016) San Diego”**

This is for your information and records

Thanking You,  
Yours faithfully,  
For **Suvan Life Sciences Limited**

  
**K. Hanumantha Rao**  
Company Secretary

## Suvan Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suvan.com website: www.suvan.com

## News Release

### **Suven Life Sciences presenting at Society for Neuroscience (SFN-2016) San Diego.**

**HYDERABAD, INDIA (November 14th, 2016)** – Suven Life Sciences is participating and presenting positive Pre-clinical and Phase-1 clinical data of several advanced molecules from their portfolio of new chemical entities (NCEs) and the status of Phase 2 clinical trial of their lead compound SUVN-502 at SFN 2016 being held at San Diego, USA during 12-16, 2016. Neuroscience is the annual meeting of the Society for Neuroscience (SFN) and more than 30 thousand Neuro-Scientists from all over the world covering the major Pharma, Biotech and Clinical Research institutes will be participating at this conference

**Key pharmacology, ADME, Safety and Phase-2 clinical trial status of SUVN-502 (5-HT6 receptor antagonist), Phase 1 clinical data of SUVN-G3031 (Histamine-3 receptor antagonist) and SUVN-D4010 (5-HT4 receptor partial agonist) along with CB2 agonist and Muscarinic (M1) acetylcholine receptor positive allosteric modulators (PAM) to treat the unmet medical needs of patients living with cognitive dysfunction associated with Alzheimer's, Schizophrenia, ADHD; Depression & Mood Disorders and Neuropathic Pain are being presented by Suven scientists at SFN-2016. These data presentations highlight Suven's continued commitment to explore new treatment options addressing unmet medical need through novel mechanisms and targets and address a market size of more than \$35 billion.**

**Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. Suven has 4 clinical stage compounds, a Phase 2 undergoing SUVN-502, Phase 1 completed SUVN-G3031 and SUVN-D4010 for Alzheimer's disease and Schizophrenia along with Phase 1 ready SUVN-911 for Major Depressive Disorder (MDD). In addition to that the Company has nine (9) internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and pain.**

For more information please visit our Web site at <http://www.suven.com>

***Risk Statement:***

*Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.*

## **Suven Life Sciences Limited**

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: [info@suven.com](mailto:info@suven.com) website: [www.suven.com](http://www.suven.com)